IP Library Granted Patent US 10,952,983
Granted Patent B2
US 10,952,983 · App. 16/710,302 · Granted Mar 23, 2021

Metabolism-improving agent comprising rare fatty acid

Inventors: Jun Ogawa (Kyoto, JP); Shigenobu Kishino (Kyoto, JP); Teruo Kawada (Kyoto, JP); Nobuyuki Takahashi (Kyoto, JP); Tsuyoshi Goto (Kyoto, JP); Yasunori Yonejima (Muko, JP)
Assignees: KYOTO UNIVERSITY; NITTO PHARMACEUTICAL INDUSTRIES, LTD.
A61K31/202A23L33/12A61K31/20A61K31/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,952,983
App. No.
16/710,302
Granted
Mar 23, 2021
Kind
B2
Abstract

The invention provides a metabolism improving agent containing a rare fatty acid such as hydroxylated fatty acid, oxo fatty acid and the like, and further, food, pharmaceutical product and the like containing the metabolism improving agent.

Claims (8)

1. A method for treating hyperlipidemia comprising administering to a patient an effective amount of a fatty acid selected from the group consisting of

13-hydroxy-cis-6, cis-9, cis-15-octadecatrienoic acid, 10,13-dihydroxy-cis-6, cis-15-octadecadienoic acid, 10-oxo-13-hydroxy-cis-6-octadecenoic acid, 10-oxo-13-hydroxy-cis-6,cis-15-octadecadienoic acid, 13-hydroxy-cis-5,cis-9-octadecadienoic acid, 13-hydroxy-trans-5,cis-9-octadecadienoic acid, 13-oxo-cis-6, cis-9, cis-15-octadecatrienoic acid, 10,13-dioxo-cis-6-octadecenoic acid, 10,13-dioxo-cis-6, cis-15-octadecadienoic acid, 13-oxo-cis-5,cis-9-octadecadienoic acid, 13-oxo-trans-5,cis-9-octadecadienoic acid,

15-hydroxy-cis-11,cis-17-eicosadienoic acid, 15-hydroxy-cis-8,cis-11-eicosadienoic acid, 15-hydroxy-cis-8,cis-11,cis-17-eicosatrienoic acid, 15-hydroxy-cis-5,cis-11-eicosadienoic acid, 15-hydroxy-cis-5,cis-11,cis-17-eicosatrienoic acid, 15-oxo-cis-11,cis-17-eicosadienoic acid, 15-oxo-cis-8,cis-11-eicosadienoic acid, 15-oxo-cis-8,cis-11,cis-17-eicosatrienoic acid, 15-oxo-cis-5,cis-11-eicosadienoic acid, 15-oxo-cis-5,cis-11,cis-17-eicosatrienoic acid,

12-hydroxy-cis-14-eicosenoic acid, 12-hydroxy-cis-14,cis-17-eicosadienoic acid, 12-hydroxy-cis-8,cis-14,cis-17-eicosatrienoic acid, 12-oxo-cis-14-eicosenoic acid, 12-oxo-cis-14,cis-17-eicosadienoic acid, 12-oxo-cis-8,cis-14-eicosadienoic acid, 12-oxo-cis-5,cis-8-eicosadienoic acid, and 12-oxo-cis-8,cis-14,cis-17-eicosatrienoic acid.

2. A method for promoting a PPAR activity, wherein the PPAR is PPARa or PPARγ, comprising administering to a patient an effective amount of a fatty acid selected from the group consisting of

13-hydroxy-cis-6,cis-9,cis-15-octadecatrienoic acid, 10,13-dihydroxy-cis-6,cis-15-octadecadienoic acid, 10-oxo-13-hydroxy-cis-6-octadecenoic acid, 10-oxo-13-hydroxy-cis-6,cis-15-octadecadienoic acid, 13-hydroxy-cis-5,cis-9-octadecadienoic acid, 13-hydroxy-trans-5,cis-9-octadecadienoic acid, 13-oxo-cis-6,cis-9,cis-15-octadecatrienoic acid, 10,13-dioxo-cis-6-octadecenoic acid, 10,13-dioxo-cis-6,cis-15-octadecadienoic acid, 13-oxo-cis-5,cis-9-octadecadienoic acid, 13-oxo-trans-5,cis-9-octadecadienoic acid,

15-hydroxy-cis-11,cis-17-eicosadienoic acid, 15-hydroxy-cis-8,cis-11-eicosadienoic acid, 15-hydroxy-cis-8,cis-11,cis-17-eicosatrienoic acid, 15-hydroxy-cis-5,cis-11-eicosadienoic acid, 15-hydroxy-cis-5,cis-11,cis-17-eicosatrienoic acid, 15-oxo-cis-11,cis-17-eicosadienoic acid, 15-oxo-cis-8,cis-11-eicosadienoic acid, 15-oxo-cis-8,cis-11,cis-17-eicosatrienoic acid, 15-oxo-cis-5,cis-11-eicosadienoic acid, 15-oxo-cis-5,cis-11,cis-17-eicosatrienoic acid,

12-hydroxy-cis-14-eicosenoic acid, 12-hydroxy-cis-14,cis-17-eicosadienoic acid, 12-hydroxy-cis-8,cis-14,cis-17-eicosatrienoic acid, 12-oxo-cis-14-eicosenoic acid, 12-oxo-cis-14,cis-17-eicosadienoic acid, 12-oxo-cis-8,cis-14-eicosadienoic acid, 12-oxo-cis-5,cis-8-eicosadienoic acid, and 12-oxo-cis-8,cis-14,cis-17-eicosatrienoic acid.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2024
From: OGAWA, JUN; KISHINO, SHIGENOBU; KAWADA, TERUO; TAKAHASHI, NOBUYUKI; GOTO, TSUYOSHI; YONEJIMA, YASUNORI
To: KYOTO UNIVERSITY; NITTO PHARMACEUTICAL INDUSTRIES, LTD.
Reel/Frame 068942/0231 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE PROPERTY TYPE FROM APPLICATION NUMBER TO PATENT NUMBER FOR 10952983 AND 10975397 PREVIOUSLY RECORDED AT REEL: 68851 FRAME: 663. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 18, 2024
From: KYOTO UNIVERSITY
To: NOSTER INC.
Reel/Frame 069207/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2021
From: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
To: NOSTER INC.
Reel/Frame 055920/0263 →
Priority Claims (1)
JP 2014-011871 · Jan 24, 2014 · national
Continuity (2)
Division 15113654
Related Publication 20200101036A1 · Apr 2, 2020